Bas Ebaid (PhD), MBA Candidate

Dedicated medical affairs professional with expertise in stakeholder collaboration, strategic planning, and broad therapeutic area knowledge. Currently serving as Associate Medical Manager and Medical Science Liaison at Eisai Australia, leading national therapeutic initiatives in gynecological, thyroid, and breast cancers. Adept at leveraging scientific expertise and strategic insights to drive medical initiatives, engage with key stakeholders, and align with business objectives. Experience spans oncology, respiratory disease, immunology, and solid tumor clinical trials coordination.

I hold a PhD from the Olivia Newton-John Cancer Research Institute, specialising in translational cancer research with a focus on epigenetic modifications in cancer predisposition. Strong foundation in oncology, genomic testing, and personalized medicine. Actively contributes to leadership and advisory roles, including Higher Education Academic Board Member, Advisory Committee Member, Hospice Volunteer at VSK, and STEM student mentor, fostering the next generation of scientific talent.

Currently pursuing an MBA to expand business acumen and leadership skills. Known for adaptability, reliability, and a commitment to excellence in fast-paced settings. Passionate about promoting disease awareness, equitable healthcare access, and innovative research. Strives to improve patient care and quality of life through professional expertise and volunteer efforts.

• 2023, Clinical Oncology Society of Australia, Melbourne, Australia, Updated efficacy and safety of lenvatinib + pembrolizumab vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
• 2022, Clinical Oncology Society of Australia, Brisbane, Australia, Characterization & management of adverse reactions in patients with advanced RCC receiving Lenvatinib and pembrolizumab (CLEAR study), Updated Efficacy of Lenvatinib + Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma in the CLEAR Study
• 2019, American Association for Cancer Research (AACR), Atlanta, GA, A case-control study of constitutional BRCA1 methylation in a mammographically screened cohort
• 2019, Victorian Comprehensive Cancer Centre Conference, Melbourne, Australia, Constitutional BRCA1 methylation in a mammographically screened cohort: a case-control study
• 2019, Cancer Biology Forum, La Trobe University, Melbourne, Australia, Constitutional BRCA1 methylation in breast cancer predisposition
• 2019, Business in Fashion, Philanthropy Event for ONJCRI, Melbourne, Australia, Oral presentation and Q&A with members of the public about ongoing research at the Olivia Newton-John Cancer Research Institute
• 2018, Blue Illusion, Melbourne, Australia, Oral presentation and Q&A about ongoing research at the Olivia Newton-John Cancer Research Institute

• MAPA Executive Committee Member, 2024 - Present
• Advisory Committee Member for Medical Science, SMEC.AI, 2024 - Present
• La Trobe University Industry Mentoring Program – Mentor, 2024 - Present
• Higher Education Academic Board Member, Mayfield Tertiary Education, 2022 - Present
• Very Special Kids (VSK) – Hospice volunteer, 2018 - Present

• 2023, Evolve Core: Introduction to Leadership, Eisai
• 2022, International Council for Harmonisation - Good Clinical Practice (ICH-GCP) E6 R2
• 2022, Medicines Australia Code of Conduct – Program 1
• 2019, Safe Transport of Infectious Substances by Air, Civil Aviation Safety Authority (CASA)
• 2018, Applied GCP for Investigational Sites and Sponsors, ARCS (certificate 1, 2 & 3)

• Medical Affairs Professionals of Australia (MAPA), 2024 - Present
• The Association of Regulatory and Clinical Scientists (ARCS), 2018 - Present